Bharat Biotech to Upgrade Covaxin Facilities

World Health Organization (WHO) suspended the supply of Bharat Biotech's Covaxin vaccine last month.

The supply of Bharat Biotech's Covaxin vaccine has been suspended by the World Health Organization (WHO) under the United Nations (UN) procurement after inspection last month.

The company has said it is working on upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.

Two Year Old Gets Covaxin Trial Vaccine Shot in UP
Five children, including three girls and two boys, who were in the age group of 2-6 years were given the Covid vaccine in Kanpur Dehat during the ongoing trial of Bharat Biotech's Covaxin on children.

‘Bharat Biotech slows down the production of Covaxin across its manufacturing facilities.’

The WHO said in a statement late on on Saturday that the Covaxin suspension was in response to the outcomes of its post EUL (emergency use authorization) inspection, held between March 14-22, and the need to conduct process and facility upgrades to address recently identified GMP (good manufacturing practice) deficiencies.

"The World Health Organization (WHO) is today confirming the suspension of supply of Covaxin produced by Bharat (Biotech) through UN procurement agencies and recommending to countries that received the vaccine to take actions as appropriate," the global health agency said.

Bharat Biotech on Sunday said it had nothing else to add to an earlier statement where it said it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.

Covaxin Has Undergone All Necessary Trials: SC
Phase 3 efficacy trial of Covaxin revealed that the vaccine is 77.8 percent effective against Covid-19 infection.

"During the recent WHO post EUL inspection, Bharat Biotech agreed with the WHO team on the scope of the planned improvement activities and indicated that they will be executed as soon as practical," it had said in a statement on April 1.

Hyderabad-based vaccine manufacturer Bharat Biotech then announced the temporary slowing down of its Covid vaccine Covaxin's production across its manufacturing facilities.

Newborn Calf Serum is Used Only for Preparing Covaxin
The Indian Health Ministry clarified that the newborn calf serum is used only for the preparation and growth of vero cells of Bharat Biotech's Covaxin.

"Bharat Biotech announces the temporary slowing down of production of Covaxin across its manufacturing facilities, having completed its supply obligations to procurement agencies and foreseeing the decrease in demand," it said.

The company will focus on pending facility maintenance, process and facility optimization activities for the coming period, it said.

India can Supply 5 Billion Covaxin Dosages to World
India continued to be a trusted partner in the context of reliable supply chains, the IT sector, the BPOs, despite the challenges faced during the pandemic.

Source-IANS